Promoting, improving and accelerating the drug development and approval processes

Drug News and Perspectives

Volumn 22, Issue 1, 2009, Pages 30-38

  Graul, Ann I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; AZACITIDINE; BECLOMETASONE DIPROPIONATE; BUPIVACAINE; CARBON MONOXIDE; CATUMAXOMAB; CLOBAZAM; CLONAZEPAM; COLISTIMETHATE; DIMETHYL SULFOXIDE; EVEROLIMUS; FLUOXETINE; LENALIDOMIDE; LUMILIXIMAB; MELPHALAN; MEPOLIZUMAB; MIGLUSTAT; NIMOTUZUMAB; OBLIMERSEN; ORPHAN DRUG; PRALATREXATE; PRAMIPEXOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RESVERATROL; SARSASAPOGENIN; TERGURIDE; TETRATHIOMOLYBDATE AMMONIUM; TRABECTEDIN; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; CLINICAL RESEARCH; DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG PROGRAM; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; METHODOLOGY; RARE DISEASE; RESEARCH ETHICS; TROPICAL DISEASE; UNITED STATES;

EID: 62649091286     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.1.1303816     Document Type: Article

References (31)

1. Food and Drug Administration. Innovation or stagnation: Challenges and opportunity on the critical path to new medical products. U.S. Department of Health and Human Services, 2004. http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html. Accessed November 13, 2008.
2. Graul, A.I. Promoting, improving and accelerating the drug development and approval processes. Drug News Perspect 2008, 21(1): 36-43.
3. FDA Office of Orphan Products Development. Cumulative list of all orphan designated and or approved products. May 16, 2008. http://www.fda.gov/orphan/designat/alldes.rtf. Accessed November 5, 2008.
4. FDA Office of Orphan Products Development. Cumulative list of designated approved orphan products. May 15, 2008. http://www.fda.gov/orphan/designat/allap.rtf. Accessed November 5, 2008.
5. Orphanet Reports Series. List of marketing authorised orphan drugs in Europe. July 2008. http://www.orpha.net/orphacom/cahiers/docs/GB/ List_of_marketing_orphan_drugs_in_Europe.pdf. Accessed November 5, 2008.
6. Reichert, J.M., Rochon, S.L. and Zhang, B.D. A decade of the Fast Track programme. Nat Rev Drug Dis 2008, 7(11): 885-6.
7. Reichert, J.M., Rochon, S.L. and Zhang B.D. Finding value in the U.S. Food and Drug Administration's Fast Track program. Drug News Perspect 2009, 22(1): 61-66.
8. Doroshow, J.H. and Parchment, R.E. Oncologic phase 0 trials incorporating clinical pharmacodynamics: From concept to patient. Clin Cancer Res 2008, 14(12): 3658-63.
9. Guidance for Industry, Investigators and Reviewers: Exploratory IND Studies. Center for Drug Evaluation and Research/U.S. FDA, January 2006. http://www.fda.gov/cder/guidance/7086fnl.pdf. Accessed November 12, 2008.
10. Kinders, R., Parchment, R.E., Ji, J. et al. Phase 0 clinical trials in cancer drug development: From FDA guidance to cfinicof practice. Mol Interv 2007, 7(6): 325-34.
11. Takimoto, C.H. Phase 0 clinical trials in oncology: A paradigm shift for early drug development? Cancer Chernother Pharmacol 2008, July 10 (Epub ahead of print).
12. Murgo, A.J., Kummar, S., Rubinstein, L. et al. Designing phase 0 cancer clinical trials. Clin Cancer Res 2008, 14(12): 3675-82.
13. Kummar, S., Rubinstein, L., Kinders, R. et al. Phase 0 clinical trials: Conceptions and misconceptions. Cancer J 2008, 14(3): 133-7.
14. Xceleron Microclosing Webinar, July 10, 2008. Available at http://www.xceteron.com/metadot/index.pl?iid=2761. Accessed November 17, 2008.
15. Eliopoulos, H., Giranda, V., Carr, R., Tiehen, R., Leahy, T. and Gordon, G. Phase 0 trials: An industry perspective. Clin Cancer Res 2008, 14(12): 3683-8.
16. Kummar, S. et al. Inhibition of poly (ADP-ribose) polymerose (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial. J Clin Oncol 2007, 25(18, Suppl.): Abst 3518.
17. Johnson, G. Using microdosing to enhance development - Early availability of PK information allows for selection of potentially promising molecules. Genetic Engineering Biotechnology News, 2008, 28(19). Available at http://www.genengnews.com/articles/ chtitem.aspx?tid=2670. Accessed November 17, 2008.
18. New data further strengthens case for microdosing in drug development. Xceleron news release, June 19, 2008. Available at http://www.xceleron.com/metadot/index.pl?id=2754&isa= DBRow&op=show&dbview_id=2596. Accessed November 17, 2008.
19. 14C Labeling of Biologics. November 12, 2008 ' Available at http://www.xceleron.com/metadot/ index.pl?id=2790&isa=Category&op=show. Accessed November 17, 2008.
20. Kimmelman, J. Ethics at phase 0: Clarifying the issues. J Law Med Ethics 2007, 35(4): 727-33.
21. Abdoler, E., Taylor, H., Wendler, D. The ethics of phase 0 oncology trials. Clin Cancer Res 2008, 14(12): 3692-7.
22. Department of Health and Human Services/U.S. Food and Drug Administration. Pharmaceutical quality for the 27st century: A risk-based approach. Progress report. May 2007. Available at http://www.fda.gov/oc/cgmp/report0507.html. Accessed November 17, 2008.
23. Yu, L.X. Pharmaceutical quality by design: Product and process development, understanding, and control. Pharmaceut Res 2008, 25(4): 781-91.
24. Winkle, H.N. Implementing quality by design. PDA/FDA Joint Regulatory Conference: Evolution of the global regulatory environment - A practical approach to change. September 24, 2007. Available at http://www.fda.gov/Cder/OPS/ImplementingQualitybyDesign.pdf. Accessed November 17, 2008.
25. Food and Drug Administration docket number FDA-2008-N-0355. Submission of quailty information for biotechnology products in the Office of Biotechnology Products; Notice of pilot program. July 2, 2008. Available at http://www.fda.gov/OHRMS/DOCKETS/98fr/E8-14999.htm. Accessed November 17, 2008.
26. Trouiller, P., Olliaro, P., TorreeLe, E., Orbinski, J., Laing, R. and Ford, N. Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet 2002, 359(9339): 1102.
27. U.S. Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research. Guidance for industry: Tropical disease priority review vouchers. Draft guidance (October 2008). Available at http://www.fda.gov/OHRMS/DOCKETS/98fr/ FDA-2008-D-0530-gdL.pdf. Accessed December 12, 2008.
28. Kesselheim, A.S. Drug development for neglected diseases - The trouble with FDA review vouchers. N Engl J Med 2008, 359(19): 1981-3.
29. Ridley, D.B., Grabowski, H.G. and Moe, J.L. Developing drugs for developing countries. Health Affairs 2006, 25(2): 313-24.
30. US FDA priority review vouchers: An effective incentive to develop drugs and vaccines for neglected diseases? International AIDS Vaccine Initiative (IAVI) technical note (2008). Available at https://www.iavi.org/viewfile.cfm?fid=4796. Accessed December 12, 2008.
31. FDA issues draft guidance on priority review vouchers. BIO Ventures for Global Health to work with industry to educate, promote PRV program. BIO Ventures for Global Health news release, October 20, 2008.